Skip to Main Content

Paper Details

GLUT3 inhibitor discovery through in silico ligand screening and in vivo validation in eukaryotic expression systems.
Sci Rep
9
2022
200 ligand, Class 1 GLUT, G3iA, G3iD, GLUT, GLUT1, GLUT1-5, GLUT2, GLUT3, GLUT4, GLUT5, SLC2 gene family, cancer, cancer cells, cancers, eukaryotic expression systems, glucose, glucose transporter, glucose transporter family, hexose, hexose transporter, hexose transporter-deficient yeast cells, hexoses, human, human cells, multiple myeloma, neurodegenerative diseases, neurons, yeast
Author NameAffiliation
Giovanni BocciThe University of New Mexico School of Medicine
Tudor I OpreaThe University of New Mexico School of Medicine
Tudor I OpreaUNM Comprehensive Cancer Center, The University of New Mexico
Tudor I OpreaInstitute of Medicine, University of Gothenburg
Tudor I OpreaNovo Nordisk Foundation Center for Protein Research, University of Copenhagen
Tudor I OpreaThe University of New Mexico School of Medicine
Tudor I OpreaUNM Comprehensive Cancer Center, The University of New Mexico
Tudor I OpreaInstitute of Medicine, University of Gothenburg
Tudor I OpreaNovo Nordisk Foundation Center for Protein Research, University of Copenhagen
  • 1 - 9

Datasets

Release 1.2